| Dr Stuart N Pollack, MD | |
|
801 Ostrum St, Bethlehem, PA 18015 | |
| (484) 526-4000 | |
| (706) 653-1230 |
| Full Name | Dr Stuart N Pollack |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 35 Years |
| Location | 801 Ostrum St, Bethlehem, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023003233 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0204X | Radiology - Vascular & Interventional Radiology | MD054086L (Pennsylvania) | Secondary |
| 2085R0202X | Radiology - Diagnostic Radiology | MD054086L (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Luke's Hospital Bethlehem | Bethlehem, PA | Hospital |
| St Luke's Hospital - Anderson Campus | Easton, PA | Hospital |
| St Lukes Quakertown Hospital | Quakertown, PA | Hospital |
| St Luke's Warren Hospital | Phillipsburg, NJ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Progressive Physician Assoc Inc | 1355243809 | 118 |
| Progressive Physician Assoc Inc | 1355243809 | 118 |
News Archive
Transcept Pharmaceuticals, Inc. today announced that it is scheduled to meet with the U.S. Food and Drug Administration (FDA) on January 20, 2010 to discuss the Complete Response Letter regarding the New Drug Application (NDA) for Intermezzo® (zolpidem tartrate sublingual tablet). As previously announced, the Complete Response Letter, received by Transcept on October 28, 2009, indicated that the FDA could not approve the NDA in its present form.
Solta Medical, Inc. (Nasdaq: SLTM) is proud to celebrate the launch of the new Thermage CPT and Fraxel re:store Dual systems with the kick off of the illumiNATION tour (www.illumiNATIONtour.com). Starting September 14 and continuing through November, the illumiNATION tour is bringing the latest breakthroughs in Thermage(R) and Fraxel(R) systems directly to physicians in over 20 cities across the U.S. and 11 cities in Europe.
A new drug, eprotirome, has been shown to significantly lower bad cholesterol, triglycerides and Lp(A), without the side effects that statins cause in many people. Results of a study were published today in the New England Journal of Medicine.
GlaxoSmithKline and XenoPort, Inc. (Nasdaq: XNPT) today announced that the U.S. Food and Drug Administration (FDA) has extended the original Prescription Drug User Fee Act (PDUFA) goal date for its review of the New Drug Application (NDA) for GSK1838262/XP13512 (gabapentin enacarbil) to February 9, 2010. The original PDUFA date for this NDA review was November 9, 2009.
› Verified 3 days ago
| Entity Name | Diagnostic Imaging Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093786410 PECOS PAC ID: 1254231087 Enrollment ID: O20040109000455 |
News Archive
Transcept Pharmaceuticals, Inc. today announced that it is scheduled to meet with the U.S. Food and Drug Administration (FDA) on January 20, 2010 to discuss the Complete Response Letter regarding the New Drug Application (NDA) for Intermezzo® (zolpidem tartrate sublingual tablet). As previously announced, the Complete Response Letter, received by Transcept on October 28, 2009, indicated that the FDA could not approve the NDA in its present form.
Solta Medical, Inc. (Nasdaq: SLTM) is proud to celebrate the launch of the new Thermage CPT and Fraxel re:store Dual systems with the kick off of the illumiNATION tour (www.illumiNATIONtour.com). Starting September 14 and continuing through November, the illumiNATION tour is bringing the latest breakthroughs in Thermage(R) and Fraxel(R) systems directly to physicians in over 20 cities across the U.S. and 11 cities in Europe.
A new drug, eprotirome, has been shown to significantly lower bad cholesterol, triglycerides and Lp(A), without the side effects that statins cause in many people. Results of a study were published today in the New England Journal of Medicine.
GlaxoSmithKline and XenoPort, Inc. (Nasdaq: XNPT) today announced that the U.S. Food and Drug Administration (FDA) has extended the original Prescription Drug User Fee Act (PDUFA) goal date for its review of the New Drug Application (NDA) for GSK1838262/XP13512 (gabapentin enacarbil) to February 9, 2010. The original PDUFA date for this NDA review was November 9, 2009.
› Verified 3 days ago
| Entity Name | Progressive Physician Assoc Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881646859 PECOS PAC ID: 1355243809 Enrollment ID: O20040123000977 |
News Archive
Transcept Pharmaceuticals, Inc. today announced that it is scheduled to meet with the U.S. Food and Drug Administration (FDA) on January 20, 2010 to discuss the Complete Response Letter regarding the New Drug Application (NDA) for Intermezzo® (zolpidem tartrate sublingual tablet). As previously announced, the Complete Response Letter, received by Transcept on October 28, 2009, indicated that the FDA could not approve the NDA in its present form.
Solta Medical, Inc. (Nasdaq: SLTM) is proud to celebrate the launch of the new Thermage CPT and Fraxel re:store Dual systems with the kick off of the illumiNATION tour (www.illumiNATIONtour.com). Starting September 14 and continuing through November, the illumiNATION tour is bringing the latest breakthroughs in Thermage(R) and Fraxel(R) systems directly to physicians in over 20 cities across the U.S. and 11 cities in Europe.
A new drug, eprotirome, has been shown to significantly lower bad cholesterol, triglycerides and Lp(A), without the side effects that statins cause in many people. Results of a study were published today in the New England Journal of Medicine.
GlaxoSmithKline and XenoPort, Inc. (Nasdaq: XNPT) today announced that the U.S. Food and Drug Administration (FDA) has extended the original Prescription Drug User Fee Act (PDUFA) goal date for its review of the New Drug Application (NDA) for GSK1838262/XP13512 (gabapentin enacarbil) to February 9, 2010. The original PDUFA date for this NDA review was November 9, 2009.
› Verified 3 days ago
| Entity Name | Parlee & Tatem Radiologic Associates Ltd |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1336137090 PECOS PAC ID: 4587555099 Enrollment ID: O20040323001730 |
News Archive
Transcept Pharmaceuticals, Inc. today announced that it is scheduled to meet with the U.S. Food and Drug Administration (FDA) on January 20, 2010 to discuss the Complete Response Letter regarding the New Drug Application (NDA) for Intermezzo® (zolpidem tartrate sublingual tablet). As previously announced, the Complete Response Letter, received by Transcept on October 28, 2009, indicated that the FDA could not approve the NDA in its present form.
Solta Medical, Inc. (Nasdaq: SLTM) is proud to celebrate the launch of the new Thermage CPT and Fraxel re:store Dual systems with the kick off of the illumiNATION tour (www.illumiNATIONtour.com). Starting September 14 and continuing through November, the illumiNATION tour is bringing the latest breakthroughs in Thermage(R) and Fraxel(R) systems directly to physicians in over 20 cities across the U.S. and 11 cities in Europe.
A new drug, eprotirome, has been shown to significantly lower bad cholesterol, triglycerides and Lp(A), without the side effects that statins cause in many people. Results of a study were published today in the New England Journal of Medicine.
GlaxoSmithKline and XenoPort, Inc. (Nasdaq: XNPT) today announced that the U.S. Food and Drug Administration (FDA) has extended the original Prescription Drug User Fee Act (PDUFA) goal date for its review of the New Drug Application (NDA) for GSK1838262/XP13512 (gabapentin enacarbil) to February 9, 2010. The original PDUFA date for this NDA review was November 9, 2009.
› Verified 3 days ago
| Entity Name | Pottstown Clinic Company Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1649341934 PECOS PAC ID: 6406857184 Enrollment ID: O20070123000573 |
News Archive
Transcept Pharmaceuticals, Inc. today announced that it is scheduled to meet with the U.S. Food and Drug Administration (FDA) on January 20, 2010 to discuss the Complete Response Letter regarding the New Drug Application (NDA) for Intermezzo® (zolpidem tartrate sublingual tablet). As previously announced, the Complete Response Letter, received by Transcept on October 28, 2009, indicated that the FDA could not approve the NDA in its present form.
Solta Medical, Inc. (Nasdaq: SLTM) is proud to celebrate the launch of the new Thermage CPT and Fraxel re:store Dual systems with the kick off of the illumiNATION tour (www.illumiNATIONtour.com). Starting September 14 and continuing through November, the illumiNATION tour is bringing the latest breakthroughs in Thermage(R) and Fraxel(R) systems directly to physicians in over 20 cities across the U.S. and 11 cities in Europe.
A new drug, eprotirome, has been shown to significantly lower bad cholesterol, triglycerides and Lp(A), without the side effects that statins cause in many people. Results of a study were published today in the New England Journal of Medicine.
GlaxoSmithKline and XenoPort, Inc. (Nasdaq: XNPT) today announced that the U.S. Food and Drug Administration (FDA) has extended the original Prescription Drug User Fee Act (PDUFA) goal date for its review of the New Drug Application (NDA) for GSK1838262/XP13512 (gabapentin enacarbil) to February 9, 2010. The original PDUFA date for this NDA review was November 9, 2009.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Stuart N Pollack, MD Po Box 678398, Dallas, TX 75267-8398 Ph: (800) 475-6112 | Dr Stuart N Pollack, MD 801 Ostrum St, Bethlehem, PA 18015 Ph: (484) 526-4000 |
News Archive
Transcept Pharmaceuticals, Inc. today announced that it is scheduled to meet with the U.S. Food and Drug Administration (FDA) on January 20, 2010 to discuss the Complete Response Letter regarding the New Drug Application (NDA) for Intermezzo® (zolpidem tartrate sublingual tablet). As previously announced, the Complete Response Letter, received by Transcept on October 28, 2009, indicated that the FDA could not approve the NDA in its present form.
Solta Medical, Inc. (Nasdaq: SLTM) is proud to celebrate the launch of the new Thermage CPT and Fraxel re:store Dual systems with the kick off of the illumiNATION tour (www.illumiNATIONtour.com). Starting September 14 and continuing through November, the illumiNATION tour is bringing the latest breakthroughs in Thermage(R) and Fraxel(R) systems directly to physicians in over 20 cities across the U.S. and 11 cities in Europe.
A new drug, eprotirome, has been shown to significantly lower bad cholesterol, triglycerides and Lp(A), without the side effects that statins cause in many people. Results of a study were published today in the New England Journal of Medicine.
GlaxoSmithKline and XenoPort, Inc. (Nasdaq: XNPT) today announced that the U.S. Food and Drug Administration (FDA) has extended the original Prescription Drug User Fee Act (PDUFA) goal date for its review of the New Drug Application (NDA) for GSK1838262/XP13512 (gabapentin enacarbil) to February 9, 2010. The original PDUFA date for this NDA review was November 9, 2009.
› Verified 3 days ago
Lisa M Fedullo, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 425 Brighton St, #303, Bethlehem, PA 18015 Phone: 610-868-1100 Fax: 610-868-1111 | |
Grace Fan, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 801 Ostrum St, Radiation Oncology Dept, Bethlehem, PA 18015 Phone: 484-526-4841 Fax: 484-526-4671 | |
Dr. Ivan Michael Fras, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 801 Ostrum St, Bethlehem, PA 18015 Phone: 610-868-1100 Fax: 610-868-1111 | |
Dr. William W Woodruff, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 95 Highland Ave, Suite 130, Bethlehem, PA 18017 Phone: 610-868-1100 Fax: 610-868-1111 | |
William Harris Smith, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 801 Ostrum Street, Department Of Radiation Oncology, Bethlehem, PA 18015 Phone: 845-641-9461 | |
Bassam Al-mamoori, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 801 Ostrum St, Bethlehem, PA 18015 Phone: 484-526-4000 Fax: 706-653-1230 |